RISANKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE WHO FAILED 1 VS >1 PRIOR BIOLOGIC TREATMENT: RESULTS FROM THE MOTIVATE STUDY
Remo Panaccione 1
1 University of Calgary, Inflammatory Bowel Disease Center
Topic
IBD, Immunology
Session
IBD: Clinical trials IV
Conference
UEG Week Virtual 2021
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]
New to myUEG?
Social Sharing